bpc-157 vs bpc-159 Regeneration or Risk? A Narrative Review of for Musculoskeletal Healing BPC-157 Weight Loss: Evidence &

Pain reduction often appears first, followed by improved range of motion and reduced swelling

PubMed 22962027 TB-4 Phase 1 human safety first-in-human randomized, double-blind, single- and multiple-dose Phase 1 of recombinant human thymosin 4 in healthy volunteers, no serious adverse events: PubMed 34346165

Bpc-157 Dosing Guidelines Standard dosing ranges from 0.25 to 0.5 mg daily as the therapeutic range for most applications, translating to approximately 1.6 to 4 micrograms per kilogram of body weight

Preclinical data suggests that even when administered in a location far from the injury site, BPC-157 can travel through the bloodstream and exert its regenerative effects wherever damage is present

Kotani, and T

Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, et al